These findings shed light on the role of ferroptosis in CCA, and identify ACSL3 as a key ferroptosis suppressor, and suggest that the ACSL3-mediated ferroptosis resistance pathway is a potential therapeutic target in high-risk CCA patients. The gene discussed is ACSL3; the disease is cholangiocarcinoma.